Back to School: How biopharma can reboot drug development. Access exclusive analysis here

A holiday card it wasn't

CellPro Inc. got a lump of coal in its Christmas stocking from the FDA, in the form of a letter notifying the company that the PMA for its Ceprate SC Stem Cell Concentration System isn't approvable without amendment.

The agency's letter said the measures needed to make the PMA approvable include the possibility of additional studies of platelet engraftment, patient survival and other issues. CPRO hasn't yet discussed

Read the full 673 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE